Document Detail

Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.
MedLine Citation:
PMID:  232084     Owner:  NLM     Status:  MEDLINE    
Captopril inhibits angiotensin II formation and bradykinin degradation in vivo. Eleven patients with essential hypertension (EH) and four patients with renovascular hypertension (RVH) were treated with captopril for periods ranging from 3 days to 12 months. All patients had a diastolic blood pressure (DBP) over 95 mm Hg after receiving a placebo for 3 days. Captopril given in ascending doses (10-1000 mg/day) caused normalization of blood pressure in all but three patients, one with severe RVH whose pressure fell 11%, one patient with severe EH, whose pressure fell 27%, and one with EH whose blood pressure fell 8.5%. The average control DBP in patients with EH was 113.7 +/- 5.5 (SE) mm Hg and fell to 89.9 +/- 3.6 mm Hg (p less than 0.001), while DBP in patients with RVH fell from 110.7 +/- 7.6 mm Hg to 94.5 +/- 8.2 (p less than 0.005). All patients were studied in balance on a 100 mEq sodium (Na) diet. Plasma renin activity (PRA) versus 24-hour urinary Na excretion increased sevenfold during therapy while converting enzyme activity fell by about one half. The magnitude of the blood pressure response was not related to control PRA. Cardiac output was estimated by echocardiography during placebo administration and during maintenance therapy with captopril. A significant change was not observed. Total peripheral resistance fell an average of 18.9% (p less than 0.05) in 11 of the 13 patients in whom the measurement could be made. It is concluded that captopril effectively lowers blood pressure in patients with EH or RHV by reducing total peripheral resistance.
J M Sullivan; B A Ginsburg; T E Ratts; J G Johnson; B R Barton; D H Kraus; D N McKinstry; E E Muirhead
Related Documents :
396084 - Response of arterial blood pressure, plasma renin activity and plasma aldosterone conce...
11821634 - Psychological characteristics and responses to antihypertensive drug therapy.
8922744 - Renal effects of concurrent e-24.11 and ace inhibition in the aorto-venocaval fistula rat.
1395114 - The effect of hypertension and ace inhibition on arterial structure and compliance.
15564934 - Comparative evaluation of the datex-ohmeda s/5 entropy module and the bispectral index ...
22938334 - High pressure sample cell for total internal reflection fluorescence spectroscopy at pr...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Hypertension     Volume:  1     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:    1979 Jul-Aug
Date Detail:
Created Date:  1980-06-16     Completed Date:  1980-06-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  397-401     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors*
Blood Pressure / drug effects
Captopril / administration & dosage,  adverse effects,  pharmacology*
Drug Evaluation
Hemodynamics / drug effects*
Hydrocortisone / blood
Hypertension / blood,  drug therapy*
Hypertension, Renovascular / blood,  drug therapy
Middle Aged
Potassium / metabolism
Proline / analogs & derivatives*
Renin / blood
Sodium / metabolism
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 147-85-3/Proline; 50-23-7/Hydrocortisone; 62571-86-2/Captopril; 7440-09-7/Potassium; 7440-23-5/Sodium; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensin and sodium balance: their role in chronic two-kidney Goldblatt hypertension.
Next Document:  The role of angiotensin in the control of blood pressure during sodium depletion.